Technical Analysis for OCUP - Ocuphire Pharma, Inc.

Grade Last Price % Change Price Change
F 4.965 -5.25% -0.28
OCUP closed down 11.78 percent on Monday, April 12, 2021, on 2.8 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical OCUP trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish -5.25%
Stochastic Reached Oversold Weakness -5.25%
Wide Bands Range Expansion -5.25%
Oversold Stochastic Weakness -5.25%
20 DMA Resistance Bearish -16.41%
Pocket Pivot Bullish Swing Setup -16.41%
Volume Surge Other -16.41%
Outside Day Range Expansion -16.41%
Wide Bands Range Expansion -16.41%
Narrow Range Bar Range Contraction -13.80%
Older End-of-Day Signals for OCUP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lower Bollinger Band Support about 4 hours ago
3x Volume Pace about 6 hours ago
2x Volume Pace about 6 hours ago
1.5x Volume Pace about 6 hours ago
Down 5% about 6 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ocuphire Pharma, Inc. Description

Ocuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation, and commercialization of drugs in key global markets.


Sector: Healthcare
Industry: Biotechnology
Keywords: Eye Organ Systems Diabetes Inflammation Ophthalmic Ophthalmology Retina Vascular Diseases Diabetic Retinopathy Macular Edema Blindness Vision Diabetic Macular Edema Retinopathy Night Vision Molecule Product Angiogenesis Presbyopia

Is OCUP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.812
52 Week Low 1.63
Average Volume 402,323
200-Day Moving Average 5.25
50-Day Moving Average 9.05
20-Day Moving Average 6.41
10-Day Moving Average 5.93
Average True Range 0.78
ADX 20.03
+DI 22.75
-DI 25.02
Chandelier Exit (Long, 3 ATRs ) 7.48
Chandelier Exit (Short, 3 ATRs ) 7.46
Upper Bollinger Band 7.90
Lower Bollinger Band 4.93
Percent B (%b) 0.11
BandWidth 46.41
MACD Line -0.87
MACD Signal Line -0.92
MACD Histogram 0.0516
Fundamentals Value
Market Cap 56.81 Million
Num Shares 10.8 Million
Price-to-Sales 0.00
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.56
Resistance 3 (R3) 6.66 6.33 6.34
Resistance 2 (R2) 6.33 5.99 6.28 6.27
Resistance 1 (R1) 5.78 5.78 5.62 5.68 6.19
Pivot Point 5.45 5.45 5.36 5.40 5.45
Support 1 (S1) 4.90 5.11 4.74 4.80 4.29
Support 2 (S2) 4.57 4.90 4.52 4.21
Support 3 (S3) 4.02 4.57 4.14
Support 4 (S4) 3.92